The 2015 european thyroid association guidelines on diagnosis and treatment of endogenous subclinical hyperthyroidism

B. Biondi, L. Bartalena, D. S. Cooper, L. Hegedus, P. Laurberg, G. J. Kahaly

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Endogenous subclinical hyperthyroidism (SHyper) is caused by Graves' disease, autonomously functioning thyroid nodules and multinodular goitre. Its diagnosis is based on a persistently subnormal serum thyroid-stimulating hormone (TSH) level with free thyroid hormone levels within their respective reference intervals. In 2014 the European Thyroid Association Executive Committee, given the controversies regarding the treatment of Endo SHyper, formed a task force to develop clinical practice guidelines based on the principles of evidence-based medicine. The task force recognized that recent meta-analyses, including those based on large prospective cohort studies, indicate that SHyper is associated with increased risk of coronary heart disease mortality, incident atrial fibrillation, heart failure, fractures and excess mortality in patients with serum TSH levels
OriginalsprogEngelsk
TidsskriftEuropean Thyroid Journal
Vol/bind4
Udgave nummer3
Sider (fra-til)149-163
ISSN2235-0640
DOI
StatusUdgivet - 2015

Emneord

  • allergic reaction

Citer dette

Biondi, B. ; Bartalena, L. ; Cooper, D. S. ; Hegedus, L. ; Laurberg, P. ; Kahaly, G. J. / The 2015 european thyroid association guidelines on diagnosis and treatment of endogenous subclinical hyperthyroidism. I: European Thyroid Journal. 2015 ; Bind 4, Nr. 3. s. 149-163.
@article{cfba41b908894581a74fcb8d9c253a58,
title = "The 2015 european thyroid association guidelines on diagnosis and treatment of endogenous subclinical hyperthyroidism",
abstract = "Endogenous subclinical hyperthyroidism (SHyper) is caused by Graves' disease, autonomously functioning thyroid nodules and multinodular goitre. Its diagnosis is based on a persistently subnormal serum thyroid-stimulating hormone (TSH) level with free thyroid hormone levels within their respective reference intervals. In 2014 the European Thyroid Association Executive Committee, given the controversies regarding the treatment of Endo SHyper, formed a task force to develop clinical practice guidelines based on the principles of evidence-based medicine. The task force recognized that recent meta-analyses, including those based on large prospective cohort studies, indicate that SHyper is associated with increased risk of coronary heart disease mortality, incident atrial fibrillation, heart failure, fractures and excess mortality in patients with serum TSH levels",
keywords = "allergic reaction",
author = "B. Biondi and L. Bartalena and Cooper, {D. S.} and L. Hegedus and P. Laurberg and Kahaly, {G. J.}",
year = "2015",
doi = "10.1159/000438750",
language = "English",
volume = "4",
pages = "149--163",
journal = "European Thyroid Journal",
issn = "2235-0640",
publisher = "S. Karger AG",
number = "3",

}

The 2015 european thyroid association guidelines on diagnosis and treatment of endogenous subclinical hyperthyroidism. / Biondi, B.; Bartalena, L.; Cooper, D. S.; Hegedus, L.; Laurberg, P.; Kahaly, G. J.

I: European Thyroid Journal, Bind 4, Nr. 3, 2015, s. 149-163.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - The 2015 european thyroid association guidelines on diagnosis and treatment of endogenous subclinical hyperthyroidism

AU - Biondi, B.

AU - Bartalena, L.

AU - Cooper, D. S.

AU - Hegedus, L.

AU - Laurberg, P.

AU - Kahaly, G. J.

PY - 2015

Y1 - 2015

N2 - Endogenous subclinical hyperthyroidism (SHyper) is caused by Graves' disease, autonomously functioning thyroid nodules and multinodular goitre. Its diagnosis is based on a persistently subnormal serum thyroid-stimulating hormone (TSH) level with free thyroid hormone levels within their respective reference intervals. In 2014 the European Thyroid Association Executive Committee, given the controversies regarding the treatment of Endo SHyper, formed a task force to develop clinical practice guidelines based on the principles of evidence-based medicine. The task force recognized that recent meta-analyses, including those based on large prospective cohort studies, indicate that SHyper is associated with increased risk of coronary heart disease mortality, incident atrial fibrillation, heart failure, fractures and excess mortality in patients with serum TSH levels

AB - Endogenous subclinical hyperthyroidism (SHyper) is caused by Graves' disease, autonomously functioning thyroid nodules and multinodular goitre. Its diagnosis is based on a persistently subnormal serum thyroid-stimulating hormone (TSH) level with free thyroid hormone levels within their respective reference intervals. In 2014 the European Thyroid Association Executive Committee, given the controversies regarding the treatment of Endo SHyper, formed a task force to develop clinical practice guidelines based on the principles of evidence-based medicine. The task force recognized that recent meta-analyses, including those based on large prospective cohort studies, indicate that SHyper is associated with increased risk of coronary heart disease mortality, incident atrial fibrillation, heart failure, fractures and excess mortality in patients with serum TSH levels

KW - allergic reaction

U2 - 10.1159/000438750

DO - 10.1159/000438750

M3 - Journal article

VL - 4

SP - 149

EP - 163

JO - European Thyroid Journal

JF - European Thyroid Journal

SN - 2235-0640

IS - 3

ER -